Immunwork, Inc. was founded in 2014. We focus on the research, development, and commercialization of a class of new drugs, which are created based on our proprietary technology platform, for treating multiple types of cancer, a number of severe indications in autoimmune, osteoporosis, infectious, and central nervous system diseases, pathological blood clots, rejection reaction in organ transplantation, and other selected severe clinical conditions.
Currently, many companies and academic groups are racing to establish new methods for preparing antibody drug conjugates (ADCs), bispecific antibodies, multivalent antibodies, and various forms of immuno-oncology products. It is hopeful that those various advancements will bring about major therapeutic breakthroughs in the treatment of various types of cancer. Our technology platform enables the design of a class of new drugs, which we term “T-ETM pharmaceuticals”. These new drug molecules contain both targeting (T) and effector (E) moieties. As evidenced by the product candidates that have already been designed and prepared, our technology can be used to prepare ADCs, bispecific and multi-specific antibodies, and various products in versatile configurations, which have improved product homogeneity, drug payloads, target-binding valency, and consistency in the manufacturing process. The T-E configurations are expected to achieve increased efficacy and safety.
Our existing portfolio of product candidates has expanded much beyond the scopes of applications being pursued in current “magic bullet” concept and bispecific antibody approaches. The T-E molecular platform should be applicable for designing many more other product candidates not illustrated on this website. As personalized and precision medicine is becoming a major trend in pharmaceutical development, the modular design feature of T-E pharmaceuticals is especially suitable for preparing a new generation of therapeutics.
Together, everyone achieves more! We are seeking corporate partners to collaborate the development of our T-E product candidates or to utilize our T-E technology platform to design new drugs for various disease indications.
If interested, please email us at BD@immunwork.com.
Immunwork, Inc ｜Nangang District, Taipei City, Taiwan 115 ｜ +886-2789-8773